FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2983145457> ?p ?o ?g. }

• W2983145457 endingPage "vi152" @default.
• W2983145457 startingPage "vi151" @default.
• W2983145457 abstract "Abstract BACKGROUND Rosette-forming glioneuronal tumor (RGNT) is an uncommon CNS tumor originally described in the fourth ventricle characterized by a low-grade glial neoplasm admixed with a rosette-forming neurocytic component. METHODS We reviewed clinicopathologic features of 42 patients with RGNT. Targeted next-generation sequencing was performed, and genome-wide methylation profiling is underway. RESULTS The 20 male and 22 female patients had a mean age of 25 years (range 3–47) at time of diagnosis. Tumors were located within or adjacent to the lateral ventricle (n=16), fourth ventricle (15), third ventricle (9), and spinal cord (2). All 31 tumors assessed to date contained FGFR1 activating alterations, either in-frame gene fusion, kinase domain tandem duplication, or hotspot missense mutation in the kinase domain (p.N546 or p.K656). While 7 of these 31 tumors harbored FGFR1 alterations as the solitary pathogenic event, 24 contained additional pathogenic alterations within PI3-kinase or MAP kinase pathway genes: 5 with additional PIK3CA and NF1 mutations, 4 with PIK3CA mutation, 3 with PIK3R1 mutation (one of which also contained focal RAF1 amplification), 5 with PTPN11 mutation (one with additional PIK3R1 mutation), and 2 with NF1 deletion. The other 5 cases demonstrated anaplastic features including hypercellularity and increased mitotic activity. Among these anaplastic cases, 3 harbored inactivating ATRX mutations and two harbored CDKN2A homozygous deletion, in addition to the FGFR1 alterations plus other PI3-kinase and MAP kinase gene mutations seen in those RGNT without anaplasia. CONCLUSION Independent of ventricular location, RGNT is defined by FGFR1 activating mutations or rearrangements, which are frequently accompanied by mutations involving PIK3CA, PIK3R1, PTPN11, NF1, and KRAS. Whereas pilocytic astrocytoma and ganglioglioma are characterized by solitary activating MAP kinase pathway alterations (e.g. BRAF fusion or mutation), RGNT are genetically more complex with dual PI3K-Akt-mTOR and Ras-Raf-MAPK pathway activation. Rare anaplastic examples may show additional ATRX and/or CDKN2A inactivation." @default.
• W2983145457 created "2019-11-22" @default.
• W2983145457 creator A5000053055 @default.
• W2983145457 creator A5002444356 @default.
• W2983145457 creator A5003583387 @default.
• W2983145457 creator A5006262715 @default.
• W2983145457 creator A5009622394 @default.
• W2983145457 creator A5011125577 @default.
• W2983145457 creator A5012891627 @default.
• W2983145457 creator A5014633686 @default.
• W2983145457 creator A5017144621 @default.
• W2983145457 creator A5017403551 @default.
• W2983145457 creator A5021654867 @default.
• W2983145457 creator A5021872692 @default.
• W2983145457 creator A5022285692 @default.
• W2983145457 creator A5022477562 @default.
• W2983145457 creator A5022796542 @default.
• W2983145457 creator A5028306240 @default.
• W2983145457 creator A5031474146 @default.
• W2983145457 creator A5034046986 @default.
• W2983145457 creator A5034956618 @default.
• W2983145457 creator A5036554548 @default.
• W2983145457 creator A5038354675 @default.
• W2983145457 creator A5043536050 @default.
• W2983145457 creator A5047947631 @default.
• W2983145457 creator A5049126969 @default.
• W2983145457 creator A5049938267 @default.
• W2983145457 creator A5050021152 @default.
• W2983145457 creator A5051168746 @default.
• W2983145457 creator A5052983963 @default.
• W2983145457 creator A5055460959 @default.
• W2983145457 creator A5055929035 @default.
• W2983145457 creator A5060842441 @default.
• W2983145457 creator A5061250825 @default.
• W2983145457 creator A5061325274 @default.
• W2983145457 creator A5064165616 @default.
• W2983145457 creator A5066337989 @default.
• W2983145457 creator A5068697200 @default.
• W2983145457 creator A5069205198 @default.
• W2983145457 creator A5072621337 @default.
• W2983145457 creator A5072705088 @default.
• W2983145457 creator A5073387528 @default.
• W2983145457 creator A5075370305 @default.
• W2983145457 creator A5078704434 @default.
• W2983145457 creator A5080428514 @default.
• W2983145457 creator A5083711110 @default.
• W2983145457 creator A5085910888 @default.
• W2983145457 creator A5088179286 @default.
• W2983145457 creator A5090074550 @default.
• W2983145457 creator A5090305344 @default.
• W2983145457 creator A5090555830 @default.
• W2983145457 creator A5091239690 @default.
• W2983145457 date "2019-11-01" @default.
• W2983145457 modified "2023-10-18" @default.
• W2983145457 title "PATH-38. ROSETTE-FORMING GLIONEURONAL TUMOR IS DEFINED BY FGFR1 ACTIVATING ALTERATIONS WITH FREQUENT ACCOMPANYING PI3K AND MAPK PATHWAY MUTATIONS" @default.
• W2983145457 doi "https://doi.org/10.1093/neuonc/noz175.634" @default.
• W2983145457 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6847773" @default.
• W2983145457 hasPublicationYear "2019" @default.
• W2983145457 type Work @default.
• W2983145457 sameAs 2983145457 @default.
• W2983145457 citedByCount "0" @default.
• W2983145457 crossrefType "journal-article" @default.
• W2983145457 hasAuthorship W2983145457A5000053055 @default.
• W2983145457 hasAuthorship W2983145457A5002444356 @default.
• W2983145457 hasAuthorship W2983145457A5003583387 @default.
• W2983145457 hasAuthorship W2983145457A5006262715 @default.
• W2983145457 hasAuthorship W2983145457A5009622394 @default.
• W2983145457 hasAuthorship W2983145457A5011125577 @default.
• W2983145457 hasAuthorship W2983145457A5012891627 @default.
• W2983145457 hasAuthorship W2983145457A5014633686 @default.
• W2983145457 hasAuthorship W2983145457A5017144621 @default.
• W2983145457 hasAuthorship W2983145457A5017403551 @default.
• W2983145457 hasAuthorship W2983145457A5021654867 @default.
• W2983145457 hasAuthorship W2983145457A5021872692 @default.
• W2983145457 hasAuthorship W2983145457A5022285692 @default.
• W2983145457 hasAuthorship W2983145457A5022477562 @default.
• W2983145457 hasAuthorship W2983145457A5022796542 @default.
• W2983145457 hasAuthorship W2983145457A5028306240 @default.
• W2983145457 hasAuthorship W2983145457A5031474146 @default.
• W2983145457 hasAuthorship W2983145457A5034046986 @default.
• W2983145457 hasAuthorship W2983145457A5034956618 @default.
• W2983145457 hasAuthorship W2983145457A5036554548 @default.
• W2983145457 hasAuthorship W2983145457A5038354675 @default.
• W2983145457 hasAuthorship W2983145457A5043536050 @default.
• W2983145457 hasAuthorship W2983145457A5047947631 @default.
• W2983145457 hasAuthorship W2983145457A5049126969 @default.
• W2983145457 hasAuthorship W2983145457A5049938267 @default.
• W2983145457 hasAuthorship W2983145457A5050021152 @default.
• W2983145457 hasAuthorship W2983145457A5051168746 @default.
• W2983145457 hasAuthorship W2983145457A5052983963 @default.
• W2983145457 hasAuthorship W2983145457A5055460959 @default.
• W2983145457 hasAuthorship W2983145457A5055929035 @default.
• W2983145457 hasAuthorship W2983145457A5060842441 @default.
• W2983145457 hasAuthorship W2983145457A5061250825 @default.
• W2983145457 hasAuthorship W2983145457A5061325274 @default.
• W2983145457 hasAuthorship W2983145457A5064165616 @default.
• W2983145457 hasAuthorship W2983145457A5066337989 @default.
• W2983145457 hasAuthorship W2983145457A5068697200 @default.

• next